Colorectal cancer is a major health burden with 1.24 million new cases diagnosed worldwide in 2008 ([@bib7]; [@bib16]). It is a major cause of cancer deaths with an estimated 608 000 deaths attributed to colorectal cancer in 2008, accounting for 8% of all cancer deaths ([@bib7]). In the United Kingdom, nearly 40 000 new cases were identified in 2008 (info.cancerresearchuk.org). In the United Kingdom, the National Awareness and Early Diagnosis Initiative (NAEDI) has been established to improve the public\'s awareness of signs and symptoms of cancer, and to seek advice earlier that will ultimately prevent avoidable deaths ([@bib25]). It is estimated that if survival rates in England matched best rates found in Europe, then about 1700 deaths could be avoided per year ([@bib1]).

The diagnostic utility of individual so-called 'red-flag\' alarm symptoms (i.e., rectal bleeding) are limited and not necessarily specific to colorectal cancer ([@bib17]). Current guidance in the United Kingdom from the National Institute for Health and Clinical Excellence (NICE) recommends the decision for urgent referral to a specialist based on a series factors such as age, menopausal status, change of bowel habit, stool frequency, rectal bleeding, abdominal mass and anaemia ([@bib22]). However, there are suggestions that current guidance from NICE can only identify (the minority) high-risk symptomatic patients, and that the small improvement in survival in the United Kingdom (which falls behind much of Europe ([@bib4])) implies the current approach is not working ([@bib9], [@bib10]). While we do not necessarily share these views in the absence of evidence, there are clearly opportunities and a need to provide a more consistent and objective approach to assist primary care physicians in identifying patients with undiagnosed colorectal cancer.

While the usefulness of individual symptoms is limited ([@bib8]; [@bib13]; [@bib12]; [@bib23]; [@bib2]; [@bib3]), a more appropriate approach would be to base the decision for referral using a combination of multiple risk factors, by means of a multivariable prediction model. Existing approaches based on multivariable prediction models have recently been derived that indicate improved performance over single symptoms can be achieved ([@bib9]; [@bib19]). QCancer (Colorectal) are a pair of multivariable prediction models (one for men and one for women) that have recently been developed to predict the risk of having undiagnosed colorectal cancer ([@bib15]).

QCancer (Colorectal) was developed and internally validated on a large cohort of 3.6 million patients from the QRESEARCH ([www.qresearch.org](http://www.qresearch.org)) database ([@bib15]). The QRESEARCH database is a large database comprising over 12 million anonymised health records from 602 general practices throughout the United Kingdom using the EMIS computer system. QCancer (Colorectal) was developed on 2.35 million patients aged between 30 and 84 years, contributing 4798 incident cases of colorectal cancer from 4 110 382 person-years of observation between 01 January 2000 and 30 September 2010. The final prediction models included seven risk factors for women and nine risk factors for men ([Table 1](#tbl1){ref-type="table"}). Open source code to calculate the QCancer (Colorectal) scores are available from [www.qcancer.org/colorectal/](http://www.qcancer.org/colorectal/) released under the GNU Lesser General Public Licence, version 3. The performance of the QCancer (Colorectal) was assessed on a separate sample of 1.2 million patients from the same QRESEARCH database with good discriminative ability and calibration ([@bib15]).

The aim of this article is to describe the results from an independent evaluation of QCancer (Colorectal) on a large dataset of general practice records in the United Kingdom not used to derive the prediction model.

Materials and methods
=====================

Cohort selection
----------------

Study participants were patients registered between 01 January 2000 and 30 June 2008, and recorded on the THIN database ([www.thin-uk.com](http://www.thin-uk.com)). The same exclusion criteria as the original development paper were adopted ([@bib15]). Patients were excluded if they had a prior diagnosis of colorectal cancer, were registered \<12 months with the general practice, had invalid dates, were under the age of 30 years or were aged 85 years or over. Entry to the cohort was defined, as for the original development study ([@bib15]), defined as the latest of (1) the study start date, (2) date the patient registered with the practice and (3) for those patients with symptoms (abdominal pain, appetite loss, rectal bleeding, weight loss, anaemia or change in bowel habit), the date of the first recorded onset of any symptom within the study period.

Outcome measure
---------------

The primary outcome was diagnosis of colorectal cancer, which was defined as incident diagnosis of colorectal cancer during the 2 years after study (using relevant UK diagnostic Read codes). Patients without the study outcome were censored at the earliest of the date of death, date of leaving the practice study or 2 years of follow-up.

Statistical analysis
--------------------

The 2-year predicted risk of colorectal cancer for every patient in the THIN cohort was calculated using QCancer (Colorectal) risk score ([www.qcancer.org/colorectal](http://www.qcancer.org/colorectal)). Multiple imputation using all predictors plus the outcome variable was used to replace missing values for alcohol consumption for men. This involves creating multiple copies of the data and imputing the missing values with sensible values randomly selected from their predicted distribution. Ten imputed data sets were generated and results from analyses on each of the imputed data sets were combined using Rubin\'s rules to produce estimates and confidence intervals that incorporate the uncertainty of imputed values.

Predictive performance of the QCancer (Colorectal) risk score on the THIN cohort was assessed by examining measures of calibration and discrimination. Calibration refers to how closely the predicted 2-year colorectal cancer risk agrees with the observed proportions with a diagnosis of colorectal cancer within 2 years. This was assessed for each tenth of predicted risk, ensuring 10 equally sized groups, and each 5-year age band by plotting observed proportions *vs* predicted risk.

Discrimination is the ability of the risk score to differentiate between patients who experience an event during the study period and those who do not. This measure is quantified by calculating the area under the receiver operating characteristic curve *c*-statistic; a value of 0.5 represents chance and 1 represents perfect discrimination. We also calculated the *D*-statistic ([@bib27]) and *R*^2^statistic ([@bib26]) that are measures of discrimination and explained variation, respectively, and are tailored for censored survival data.

We used decision curve analysis (accounting for censored observations) to describe and compare the clinical effects of QCancer (Colorectal) ([@bib30]). Briefly, the net benefit of a model is the difference between the number of true positives and the number of false positives weighted by the odds of the selected threshold for high-risk designation. It is interpreted as the additional number of colorectal cancer cases identified without increasing the number treated unnecessarily across a range of clinically relevant treatment/referral thresholds. QCancer (Colorectal) is assessed by comparing the gain of the model over a strategy of 'investigate all\' (i.e., assume all high risk) and 'investigate none\' (i.e., all low risk). On the resulting curve, the 'investigate all\' strategy is depicted as the line that crosses the *x* axis at the value that corresponds to the incidence rate of the outcome, while the 'investigate none\' is depicted by a horizontal line at 0.

All statistical analyses were carried out in *R* (version 2.14.1) ([@bib24]) and the ICE (multiple imputation) procedure in Stata (version 11.2) ([@bib28]).

Results
=======

Between 01 January 2000 and 30 June 2008, 2 135 540 eligible patients from 364 general practices in the United Kingdom were registered in the THIN database. The 2 135 540 eligible patients contributed 3 701 761 person-years of observation (median follow-up was 2 years), among whom there were 3712 cases of colorectal cancer (1676 women and 2036 men). [Table 2](#tbl2){ref-type="table"} details the characteristics of eligible patients.

Complete data on all risk predictors were available for all women, while complete data on alcohol consumption were available for 39.4% of men (*n*=417 560). Compared with the original development cohort, the THIN cohort had more patients reporting abdominal pain, fewer patients reporting a family history of gastrointestinal cancer and more patients with missing data on alcohol consumption (22% in the development cohort compared with 60% in the THIN cohort).

[Table 3](#tbl3){ref-type="table"} reports the age--sex incidence rates of each symptom included in the QCancer (Colorectal) prediction models. All the symptoms apart from abdominal pain tended to become more common with age. During the follow-up, the crude rate of colorectal cancer was 100 per 100 000 person-years of observation with 90 per 100 000 person-years for women and 111 per 100 000 person-years for men. As per the original development cohort, incidence rates of colorectal cancer increased sharply with age.

Performance data for QCancer (Colorectal) from the original development cohort ([@bib15]) and the THIN cohort (multiple imputation (for men) and complete-case) are presented in [Table 4](#tbl4){ref-type="table"}. The *R*^*2*^-statistics (percentage of explained variation) and the *D*-statistic were marginally higher in the THIN cohort, 65.8% and 2.84 (women) and 68.3% and 3.00 (men), compared with those reported in the original development paper, 64.8% and 2.78 (women) and 66.7% and 2.90 (men) ([@bib15]). The high values of the *D*-statistic and also the *c*-statistic 0.91 (women) and 0.92 (men) indicate very good discrimination properties of QCancer (Colorectal). The usefulness of using individual symptoms to identify patients with colorectal cancer is compared with QCancer (Colorectal) and is reported in [Table 5](#tbl5){ref-type="table"}. Using a cutoff (0.4% women and 0.5% men) that identified the 10% of women and men at the highest risk, QCancer (Colorectal) clearly outperformed with 71 and 74% of all new colorectal cancers identified for women and men, respectively. Using the presence of rectal bleeding, only 34 and 40% of new colorectal cancers were identified in women and men, respectively. Similarly, using only abdominal pain, only 36% of colorectal cancer cases in women and 31% in men were identified.

Calibration plots of QCancer (Colorectal) for women and men by tenth of risk are presented in [Figure 1](#fig1){ref-type="fig"}. Model calibration is very good with close agreement between predicted and observed colorectal cancer risks across all tenths of risk. Similarly, [Figure 2](#fig2){ref-type="fig"} displays the calibration plots of QCancer (Colorectal) for women and men by 5-year age bands. Again, the QCancer (Colorectal) shows very good agreement across all age groups, with very slight overprediction in the older age groups in both sexes, though the overprediction is small.

[Figure 3](#fig3){ref-type="fig"} displays the net benefit curves for QCancer (Colorectal), which clearly show that QCancer (Colorectal) has higher net benefit compared with the 'investigate all\' (line crossing the *x* axis at 0.2--0.25) and 'investigate none\' (horizontal line at 0) strategies.

Discussion
==========

QCancer (Colorectal) is a new risk score to identify individuals with undetected colorectal cancer in a primary care setting. The risk score was developed and internally validated on a large primary care electronic database (QRESEARCH) of 3.6 million patients contributing 7401 cases of colorectal cancer between 01 January 2000 and 30 September 2008 ([@bib15]).

QCancer (Colorectal) was designed to be a prediction model based on risk factors that are recorded in patients\' health records or which patients themselves are likely to know. Thus, QCancer (Colorectal) has potential to be a useful tool in the primary care setting to identify patients who are at an increased risk of having undiagnosed colorectal cancer who would strongly benefit from further investigation.

In the United Kingdom, the CAPER score is an alternative prediction model that uses multiple symptoms to identify patients with undiagnosed colorectal cancer that is currently being considered by the Department of Health NAEDI framework ([@bib14]; [@bib9]). However, there are several methodological concerns about how the score was derived. The handling of missing data is questionable in that patients with missing data who appear to have been omitted, thereby suggesting a complete-case analysis that has been shown to be a methodologically flawed and biased in the development of prediction models ([@bib6]; [@bib5]; [@bib20]). Using data from a single location in the United Kingdom (Exeter), the authors screened 121 risk factors using univariate associations with colorectal cancer to reduce the number of predictors, a procedure that is not recommended ([@bib29]). Furthermore, with only 349 cases of colorectal cancer the number of events per variable (\<3) ([@bib14]; [@bib9]) well below the rule-of-thumb of 10 is suggested to minimise the chance of over fitting. Lack of detailed reporting of how the score was derived and how to implement the model are also concerns ([@bib18]). More importantly owing to the design of the study (a case--control study matched on age and sex), age and sex are not included as predictors in the CAPER score despite age being a major risk factor for colorectal cancer and the incidence of symptoms varying by age. Thus, an individual with or without symptoms will have the same predicted risk using the CAPER score regardless of age or sex. There is also currently insufficient performance (validation) data conducted by independent researchers to demonstrate the predictive performance of the CAPER score.

Our independent evaluation of the performance of QCancer (Colorectal) was carried out on the large separate database (THIN) of general practice records recording clinical data using the INPS Vision system that is used in 20% of UK general practices. The database comprised 2.1 million patients between 01 January 2000 and 30 June 2008 contributing 3.7 million years of observation and 3712 cases of colorectal cancer. The performance data presented in this article on the THIN cohort provide strong evidence to support the external validity of QCancer (Colorectal) in identifying patients with suspected colorectal cancer with marginal better performance as that seen in the internal validation data. QCancer (Colorectal) also clearly outperformed the use of using individual symptoms for identifying new cases of colorectal cancer.

A limitation of our study is that the recording of symptoms might be less complete, as individuals with mild symptoms may not visit their general practitioner or even report such mild symptoms if they do consult their general practitioner.

To date, the development, internal validation and our external validation of QCancer (Colorectal) has used 5.7 million patients contributing 10 million person-years of observation and 11 113 cases of colorectal cancer during the observation periods to develop and evaluate QCancer (Colorectal) to predict the risk of colorectal cancer in adults aged 30 to 84 years. In this study, we have provided an independent and external evaluation of the QCancer (Colorectal) risk score on a large cohort of patients in the United Kingdom. We have assessed the performance of QCancer (Colorectal) against performance metrics presented in the internal validation of QCancer (Colorectal), and have provided evidence to support the use of QCancer (Colorectal) in routine clinical practice.

Implementation of QCancer (Colorectal) or indeed any other risk prediction models used in the clinical decision making and patient managed should be evaluated by independent investigators using an appropriately large data set. Ideally, any prediction model should also be evaluated in an impact study to assess whether the prediction model changes clinician behaviour and ultimately improves patients outcomes ([@bib21]; [@bib31]; [@bib11]).

Conclusions
===========

In this study, we have provided an independent and external validation of the QCancer (Colorectal) risk score on a large cohort of patients in the United Kingdom. The performance of QCancer (Colorectal) was similar to that in the internal validation with comparable results to indicating good predictive ability for identifying patients with undiagnosed colorectal cancer.
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###### Risk factors in QCancer (Colorectal)

  **Women**                                                                           **Men**
  ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Age (years)                                                                         Age (years)
  Family history of gastrointestinal cancer (yes/no)                                  Family history of gastrointestinal cancer (yes/no)
  Currently consulting a GP with first onset of abdominal pain (yes/no)               Currently consulting a GP with first onset of abdominal pain (yes/no)
  Currently consulting a GP with first onset of current appetite loss (yes/no)        Currently consulting a GP with first onset of current appetite loss (yes/no)
  Currently consulting a GP with first onset of current rectal bleeding (yes/no)      Currently consulting a GP with first onset of current rectal bleeding (yes/no)
  Currently consulting a GP with first onset of current weight loss (yes/no)          Currently consulting a GP with first onset of current weight loss (yes/no)
  Anaemia, defined as recorded haemoglobin \<11 g dl^−1^ in past 12 months (yes/no)   Anaemia, defined as recorded haemoglobin \<11 g dl^−1^ in past 12 months (yes/no)
                                                                                      Change in bowel habit in previous 12 months (yes/no)
                                                                                      Alcohol consumption (non-drinker, trivial drinker, light drinkerand moderate/heavy drinker)

Abbreviation: GP=general practitioner.

###### Characteristics of participants aged 30 to 84 years in the QRESEARCH development and THIN validation cohorts

                                                                  **QRESEARCH**    **THIN (external validation)**                    
  --------------------------------------------------------------- ---------------- -------------------------------- ---------------- ----------------
  Median age (IQR)                                                50.1 (SD=15.0)   50.1 (SD=14.9)                   49 (38, 63)      47 (38, 60)
  *Alcohol status*, n *(%)*                                                                                                          
   None                                                           510 179 (21.7)   275 152 (22.3)                   ---              127 360 (12.0)
   Trivial (\<1 unit per day)                                     656 450 (27.9)   355 654 (28.8)                   ---              161 033 (15.2)
   Light (1--2 units per day)                                     492 318 (20.9)   257 381 (20.8)                   ---              70 187 (6.6)
   Moderate or heavy (⩾3 units per day)                           175 953 (7.5)    93 075 (7.5)                     ---              58 980 (5.6)
   Alcohol status not recorded                                    516 152 (22.0)   255 339 (20.6)                   ---              642 205 (60.6)
                                                                                                                                      
  *Medical history* n *(%)*                                                                                                           
  * *Family history of gastrointestinal cancer                    29 483 (1.3)     17 672 (1.4)                     1380 (0.13)      999 (0.1)
                                                                                                                                      
  *Current symptoms and symptoms invthe preceding year*, n*(%)*                                                                       
   Current abdominal pain                                         224 880 (9.6)    125 816 (10.2)                   143 797 (13.4)   102 192 (9.6)
   Current appetite loss                                          9959 (0.4)       5358 (0.4)                       3295 (0.3)       2481 (0.2)
   Current weight loss                                            25 113 (1.1)     14 065 (1.1)                     15 398 (1.4)     12 891 (1.2)
   Current rectal bleeding                                        52 453 (2.2)     29 118 (2.4)                     27 811 (2.6)     28 423 (2.7)
   Change in bowel habit                                          3153 (0.1)       1821 (0.1)                       ---              1670 (0.2)
   Haemoglobin \<11 g dl^−1^ recorded in the last year            31 330 (1.3)     16 985 (1.4)                     13 659 (1.3)     4466 (0.4)

Abbreviation: IQR=interquartile range.

###### Incidence rates of appetite loss, weight loss, rectal bleeding and abdominal pain per 100 000 person-years by sex and age in the THIN cohort

                                  **Women**  **Men**                           
  ------------------------------ ----------- --------------------- ----------- ---------------------
  *Appetite loss (all ages)*       *3295*    *50 (49--52)*           *2481*    *39 (38--41)*
   \<35                              118     16 (13*--*19)             85      11 (9*--*13)
   35--44                            406     25 (22*--*27)             292     17 (15*--*19)
   45--54                            366     26 (23*--*28)             303     21 (18*--*23)
   55--64                            397     34 (30*--*37)             381     33 (30*--*36)
   65--74                            740     81 (77*--*87)             626     79 (73*--*85)
   75--84                           1268     197 (187*--*208)          794     192 (179*--*206)
                                                                                
  *Weight loss (all ages)*        *15 398*   *234 (231--238)*       *12 891*   *203 (199--207)*
   \<35                              655     87 (81--94)               439     55 (50--60)
   35--44                           2417     146 (141--152)           1819     106 (101--111)
   45--54                           2406     168 (161--175)           2029     138 (132--144)
   55--64                           2544     215 (206--223)           2618     225 (216--234)
   65--74                           3054     336 (324--348)           2921     369 (355--382)
   75--84                           4322     672 (653--693)           3065     740 (714--767)
                                                                                
  *Rectal bleeding (all ages)*    *27 811*   *423 (418--428)*       *28 423*   *447 (442--453)*
   \<35                             1651     220 (210--231)           1650     207 (197--217)
   35--44                           5716     346 (337--355)           6830     399 (390--409)
   45--54                           5743     401 (391--412)           6420     436 (426--447)
   55--64                           6134     517 (505--531)           5917     508 (495--521)
   65--74                           4667     513 (499--528)           4653     587 (570--604)
   75--84                           3900     607 (588--626)           2953     713 (688--739)
                                                                                
  *Abdominal Pain (all ages)*     *143 797*  *2189 (2177--2200)*    *102 192*  *1609 (1599--1619)*
   \<35                            14 268    1904 (1873--1935)        6976     874 (854--895)
   35--44                          39 869    2415 (2391--2439)       25 701    1502 (1483--1520)
   45--54                          29 526    2062 (2038--2085)       22 228    1510 (1491--1530)
   55--64                          26 356    2223 (2197--2250)       21 107    1813 (1788--1837)
   65--74                          19 825    2180 (2149--2210)       16 385    2067 (2036--2099)
   75--84                          13 953    2171 (2135--2207)        9795     2365 (2319--2413)

###### Performance data in the original development cohort and the external validation (THIN) cohort

                           **QRESEARCH ([@bib15])**              **THIN (external validation)**                                                                                            
  ------------------------ ------------------------------------- ----------------------------------- ----------------------------------------- ------------------------------------------- -----------------------------------
                           **Women (*****n*****=616** **361)**   **Men (*****n*****=620** **240)**   **Men (*****n*****=1** **059** **765)**   **Women (*****n*****=1** **075** **775)**   **Men (*****n*****=417** **560)**
  *R*^2^ (95% CI)          64.8 (63.2--66.3)                     66.7 (65.3--68.0)                   68.32 (67.32--69.32)                      65.81 (64.62--67.01)                        65.30 (63.71--66.89)
  *D*-statistic (95% CI)   2.78 (2.68--2.87)                     2.90 (2.81--2.98)                   3.00 (2.93--3.07)                         2.84 (2.76--2.92)                           2.81 (2.71--2.91)
  *c*-Statistic (95% CI)   0.89 (0.88--0.90)                     0.91 (0.90--0.91)                   0.918 (0.913--0.923)                      0.909 (0.903--0.915)                        0.901 (0.892--0.910)

Abbreviation: CI=confidence interval.

###### Comparison of strategies to identify patients of having a diagnosis of colorectal cancer in the next 2 years

  **Criterion**                      **Risk threshold (%)**   **True negative**   **False negative**   **False positive**   **True positive**   **Sensitivity (%)**   **Specificity (%)**   **Positive-predictive value (%)**   **Negative-predictive value (%)**
  ---------------------------------- ------------------------ ------------------- -------------------- -------------------- ------------------- --------------------- --------------------- ----------------------------------- -----------------------------------
  *Women*                                                                                                                                                                                                                        
   Rectal bleeding                   NA                       1 046 859           1105                 27 240               571                 34.1                  97.5                  2.1                                 99.9
   Abdominal pain                    NA                       930 900             1078                 143 199              598                 35.7                  86.7                  0.4                                 99.9
   Appetite loss                     NA                       1 070 824           1656                 3275                 20                  1.2                   99.7                  0.6                                 99.8
   Weight loss                       NA                       1 058 792           1585                 15 307               91                  5.4                   98.6                  0.6                                 99.8
   Anaemia                           NA                       1 060 613           1503                 13 486               173                 10.3                  98.7                  1.3                                 99.9
   Top 10% risk score                0.4                      970 241             491                  103 858              1185                70.7                  90.3                  1.1                                 99.9
   Top 5% risk score                 0.8                      1 021 128           739                  52 971               937                 55.9                  95.1                  1.7                                 99.9
  *Men*                                                                                                                                                                                                                          
   Rectal bleeding                   NA                       1 030 097           1245                 27 632               791                 39.9                  97.4                  2.8                                 99.9
   Abdominal pain                    NA                       956 159             1414                 101 570              622                 30.6                  90.4                  0.6                                 99.9
   Appetite loss                     NA                       1 055 272           2012                 2457                 24                  1.2                   99.8                  1.0                                 99.8
   Weight loss                       NA                       1 044 962           1912                 12 767               124                 6.1                   98.8                  1.0                                 99.8
   Change in bowel habit behaviour   NA                       1 056 108           1987                 1621                 49                  2.4                   99.8                  2.9                                 99.8
   Anaemia                           NA                       1 053 398           1901                 4331                 135                 6.6                   99.6                  3.0                                 99.8
   Top 10% risk score                0.5                      953 979             528                  103 751              1509                74.1                  90.2                  1.4                                 99.9
   Top 5% risk score                 0.9                      1 006 421           787                  51 307               1249                61.3                  95.1                  2.4                                 99.9

Abbreviation: NA=not applicable.
